New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues [Yahoo! Finance]
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: Yahoo! Finance
The company continues to see momentum in its prenatal business as well, growing 25% year over year with a 12% increase in testing volume. This volume growth reflects ongoing initiatives to improve average selling prices (ASPs). The stock carries a Zacks Rank #3 (Hold) currently. The company continues to enhance its customer targeting, digital marketing, and overall operating model to drive commercial leverage in 2024 and beyond. GeneSight revenues increased 22% in second-quarter 2024 from the comparable 2023 period, as the company reported nearly 129,000 tests. ASPs improved both on a year-over-year and quarter-over-quarter basis, reflecting improved revenue cycle management activities. Myriad Genetics announced several new exciting strategic partnerships, including a collaboration with GlaxoSmithKline to improve access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer patients. The company also partnered with QIAGEN to develop di
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $32.00 price target on the stock.MarketBeat
- Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual ConferenceGlobeNewswire
- Should You Continue to Retain MYGN Stock in Your Portfolio? [Yahoo! Finance]Yahoo! Finance
- Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics to Host Investor Event on October 9, 2024GlobeNewswire
MYGN
Earnings
- 8/6/24 - Beat
MYGN
Sec Filings
- 9/16/24 - Form 144
- 9/12/24 - Form 4
- 9/12/24 - Form 4
- MYGN's page on the SEC website